Welcome to ourH1 Report 2021

Letter from the management

Onno van de Stolpe

Letter from the management

Supported by our strong cash balance, we are convinced that the potential of our target discovery platform, our drug development capabilities, and the strength of our teams position us well for future growth. Onno van de Stolpe, CEO
Letter from the management
Bart Filius
Following the strategic exercise announced earlier this year, we are focused on advancing our refocused pipeline and implementing our savings program, while delivering on the commercial launch of Jyseleca in Europe. Bart Filius, President & COO
Letter from the management

Financial highlights

Group revenues

Group revenues

277.2 million
Read more

Cash position

Cash position

5006.6 million
Read more

Deferred income

Deferred income

2565.3 million
Read more

R&D expenditure

R&D expenditure

268.8 million
Read more